At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 365 enrolled
Drug / intervention
Exenatide once weekly suspension +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
In Brief
A Phase 3 clinical trial evaluating Exenatide once weekly suspension, Sitagliptin, and 1 other intervention for Diabetes Type 2. Completed, enrolled 365 participants across 60 sites.
Detailed Summary
To compare the effect on glycemic control (HbA1c) of exenatide suspension administered once weekly to that achieved by sitagliptin or placebo administered once daily for 28 weeks in subjects with type 2 diabetes mellitus.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Type 2
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJul 2012
Enrollment StartFeb 2013
Primary CompletionApr 2014
TodayJul 2026
First PostedJul 30, 2012
Enrollment StartFeb 1, 2013
Primary CompletionApr 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 13.9 years ago
Interventions
Exenatide once weekly suspensiondrug
Sitagliptindrug
Placebodrug
Placebo oral capsule once daily